MedTrace Logo

Polyethylene Glycol Safety in Children

NCT05424757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2025-11-04

No results posted yet for this study

Summary

The primary objective is to measure levels of selected PEG 3350 components and metabolites in the blood and urine of children who are already taking PEG 3350 compared to children who are not taking PEG 3350.

Changes to medical therapy are not recommended as part of this study.

Conditions

  • Polyethylene Glycols
  • Children, Only

Interventions

DRUG

PEG 3350

Data and biospecimens will be collected from two groups of children: * Children who have taken PEG 3350 daily for at least 30 days. * Children who have NOT taken PEG 3350 for at least 30 days. No changes to medicines are recommended as part of this study.

Sponsors & Collaborators

Principal Investigators

  • Robert O Heuckeroth, MD, PhD · Children's Hospital of Philadelphia

Eligibility

Min Age
0 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2025-08-09
Completion
2025-08-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05424757 on ClinicalTrials.gov